Big Pharma has almost reached the finish line of its decades-long battle to wipe out all competition. As of 1 April 2011—less than eight months from now—virtually all medicinal herbs will become illegal in the European Union. The approach in the United States is a bit different, but it’s having the same devastating effect. The people have become nothing more than sinks for whatever swill Big Pharma and Agribusiness choose to send our way, and we have no option but to pay whatever rates they want.
Big Pharma and Agribusiness have almost completed their march to take over every aspect of health, from the food we eat to the way we care for ourselves when we’re ill. Have no doubt about it: this takeover will steal what health remains to us.
In the nastiest April Fool’s Joke of all time, the European Directive on Traditional Herbal Medicinal Products (THMPD) was enacted back on 31 March 2004.(1) It laid down rules and regulations for the use of herbal products that had previously been freely traded.
This directive requires that all herbal preparations must be put through the same kind of procedure as pharmaceuticals. It makes no difference whether a herb has been in common use for thousands of years. The costs for this are far higher than most manufacturers, other than Big Pharma, can bear, with estimates ranging from £80,000 to £120,000 per herb, and with each herb of a compound having to be treated separately.
It matters not that a herb has been used safely and effectively for thousands of years. It will be treated as if it were a drug. Of course, herbs are far from that. They’re preparations made from biological sources. They aren’t necessarily purified, as that can change their nature and efficacy, just as it can in food. It’s a distortion of their nature and the nature of herbalism to treat them like drugs. That, of course, makes no difference in the Big Pharma-ruled edifice of the EU, which has enshrined corporatism in its constitution.
Dr. Robert Verkerk of the Alliance for Natural Health, International (ANH) describes the problem of requiring drug-like compliance on herbal preparations:
Getting a classical herbal medicine from a non-European traditional medicinal culture through the EU registration scheme is akin to putting a square peg into a round hole. The regulatory regime ignores and thus has not been adapted to the specific traditions. Such adaptation is required urgently if the directive is not to discriminate against non-European cultures and consequently violate human rights.(2)